A prognostic analysis of 895 cases of stage III colon cancer in different colon subsites
- 619 Downloads
Stage III colon cancer is currently treated as an entity with a unified therapeutic principle. The aim of the retrospective study is to explore the clinicopathological characteristics and outcomes of site-specific stage III colon cancers and the influences of tumor location on prognosis.
Eight hundred ninety-five patients with stage III colon cancer treated with radical operation and subsequent adjuvant chemotherapy (5-fluorouracil/oxaliplatin) were divided into seven groups according to colon segment (cecum, ascending colon, hepatic flexure, transverse colon, splenic flexure, descending colon, and sigmoid colon). Expression of excision repair cross-complementing group 1 (ERCC1) and thymidylate synthase (TS) was examined by immunohistochemistry. We assessed if differences exist in patient characteristics and clinic outcomes between the seven groups.
There were significant differences in tumor differentiation (P < 0.001), T stage (P < 0.001), N stage (P < 0.001), American Joint Committee on Cancer (AJCC) tumor–node–metastasis (TNM) stage (P < 0.001), metachronous liver metastasis (P < 0.001), metachronous lung metastasis (P < 0.001), and ERCCI expression (P < 0.001) between the seven groups. Both 5-year recurrence-free survival (RFS) and 5-year overall survival (OS) exhibited significant differences (both P < 0.001) with survival gradually decreasing from cecum to sigmoid colon. Cox regression analyses identified that tumor location was an independent prognostic factor for RFS and OS.
Stage III colon cancer located proximally carried a poorer survival than that located distally. Different efficacies of FOLFOX adjuvant chemotherapy may be an important factor affecting survival of site-specific stage III colon cancers.
KeywordsColon cancer Stage III Clinical characteristics Prognosis Tumor location
This study was supported by the grants from the National Nature Science Foundation of China (Nos. 30770971, 81172470, 81070362, and 81372629).
Conflict of interest
All authors declare no potential conflicts of interest.
- 11.Jess P, Hansen IO, Gamborg M, Jess T (2013) A nationwide Danish cohort study challenging the categorisation into right-sided and left-sided colon cancer. BMJ Open 3(5)Google Scholar
- 26.Papadaki C, Sfakianaki M, Ioannidis G, Lagoudaki E, Trypaki M, Tryfonidis K et al (2012) ERCC1 and BRAC1 mRNA expression levels in the primary tumor could predict the effectiveness of the second-line cisplatin-based chemotherapy in pretreated patients with metastatic non-small cell lung cancer. J Thorac Oncol 7(4):663–671CrossRefPubMedGoogle Scholar
- 34.Ciaparrone M, Quirino M, Schinzari G, Zannoni G, Corsi DC, Vecchio FM et al (2006) Predictive role of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer patients receiving adjuvant 5-fluorouracil. Oncology 70(5):366–377CrossRefPubMedGoogle Scholar
- 36.Sasako M, Terashima M, Ichikawa W, Ochiai A, Kitada K, Kurahashi I, et al (2014) Impact of the expression of thymidylate synthase and dihydropyrimidine dehydrogenase genes on survival in stage II/III gastric cancer. Gastric CancerGoogle Scholar
- 37.Dahl O, Fluge O, Carlsen E, Wiig JN, Myrvold HE, Vonen B et al (2009) Final results of a randomised phase III study on adjuvant chemotherapy with 5 FU and levamisol in colon and rectum cancer stage II and III by the Norwegian Gastrointestinal Cancer Group. Acta Oncol 48(3):368–376CrossRefPubMedGoogle Scholar
- 54.Pai RK, Jayachandran P, Koong AC, Chang DT, Kwok S, Ma L et al (2012) BRAF-mutated, microsatellite-stable adenocarcinoma of the proximal colon: an aggressive adenocarcinoma with poor survival, mucinous differentiation, and adverse morphologic features. Am J Surg Pathol 36(5):744–752CrossRefPubMedGoogle Scholar